The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 09, 2025

Filed:

Dec. 11, 2020
Applicant:

Eli Lily and Company, Indianapolis, IN (US);

Inventors:

Milata Mary Abraham, Indianapolis, IN (US);

Jorge Alsina-Fernandez, Indianapolis, IN (US);

Tamer Coskun, Carmel, IN (US);

Hongchang Qu, Carmel, IN (US);

James Lincoln Wallis, Indianapolis, IN (US);

Assignee:

ELI LILLY AND COMPANY, Indianapolis, IN (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/575 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/575 (2013.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); A61K 38/00 (2013.01);
Abstract

Incretin analogs are provided that have activity at each of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and obesity.


Find Patent Forward Citations

Loading…